ProQR Therapeutics N.V. - Ordinary Shares (PRQR) Covered Calls

You can sell covered calls on ProQR Therapeutics N.V. - Ordinary Shares to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for PRQR (prices last updated Fri 4:16 PM ET):

ProQR Therapeutics N.V. - Ordinary Shares (PRQR) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
3.82 -0.13 3.66 4.23 924K - 0.2
Covered Calls For ProQR Therapeutics N.V. - Ordinary Shares (PRQR)
Expiration Strike Call Bid Net Debit Return
If Flat
Annualized
Return If Flat
Dec 20 5 0.10 4.13 2.4% 24.3%
Jan 17 5 0.25 3.98 6.3% 35.9%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial


Extended Business Description

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It is primarily developing sepofarsen that is in phase II/III illuminate trial for treating leber's congenital amaurosis 10 disease; QR-421a, which is in phase 1/2 stellar trial for usher syndrome type 2 and non-syndromic retinitis pigmentosa; QR-1123 that is in phase 1/2 aurora trial for the treatment of autosomal dominant retinitis pigmentosa; and QR-504a, which is in first clinical trial for the treatment of fuchs endothelial corneal dystrophy. It has a license agreement with General Hospital Corporation, Radboud University Medical Center, Inserm Transfert SA, and Leiden University Medical Center. ProQR Therapeutics N.V. was founded in 2012 and is headquartered in Leiden, the Netherlands.